# A Study of TL-925 for the Treatment of Allergic Conjunctivitis

> **NCT06153342** · PHASE2 · UNKNOWN · sponsor: **Telios Pharma, Inc.** · enrollment: 70 (estimated)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** TL-925
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06153342
- **Lead sponsor:** Telios Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11
- **Primary completion:** 2024-01
- **Final completion:** 2024-01
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2023-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06153342

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06153342, "A Study of TL-925 for the Treatment of Allergic Conjunctivitis". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT06153342. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*